Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus-Reference-Cited by-同舟云学术

Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus

Published:2017-05-03 Issue:6 Volume:65 Page:1803-1809
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Lawitz Eric¹,Poordad Fred¹,Wells Jennifer¹,Hyland Robert H.²,Yang Yin²,Dvory-Sobol Hadas²,Stamm Luisa M.²,Brainard Diana M.²,McHutchison John G.²,Landaverde Carmen¹,Gutierrez Julio¹

Affiliation:

1. Texas Liver Institute; University of Texas Health Science Center; San Antonio TX

2. Gilead Sciences, Inc; Foster City CA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Hepatology

Reference16 articles.

1. Global distribution and prevalence of hepatitis C virus genotypes;Messina;Hepatology,2015

2. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs;Naggie;Annu Rev Med,2017

3. Reinventing HCV treatment: past and future perspectives;Carter;J Clin Pharmacol,2017

4. Interferon-free combination therapies for the treatment of hepatitis C: current insights;Holmes;Hepat Med,2015

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of SOF/VEL containing rescue therapy in treating chronic HCV-GT4 patients previously failed NS5A inhibitors-based DAAs;Egyptian Liver Journal;2024-03-11

2. A randomized-controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C;Journal of Hepatology;2023-08

3. The impact of sofosbuvir/velpatasvir/voxilaprevir treatment on serum hyperglycemia in hepatitis C virus infections: a systematic review and meta-analysis;Annals of Medicine;2023-01-19

4. Real World Efficacy and Safety of Sofosbuvir + Velpatasvir + Voxilaprevir in Romanian Patients with Genotype 1b HCV Infection Non-reponders to DAAs Therapy;Journal of Gastrointestinal and Liver Diseases;2022-12-17

5. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir retreatment in hepatitis C patients with different genotypes with DAAs failure in East China;2022-12-07